Please login to the form below

Not currently logged in
Email:
Password:

PhRMA objects to House bill

PhRMA is taking issue with parts of the House war supplemental bill that would prevent patent settlements between drugmakers

Pharmaceutical Research and Manufacturers of America (PhRMA) is taking issue with language in the House war supplemental bill that would prevent patent settlements between brand-name and generic drugmakers.

The settlements, often referred to as "pay for delay" deals, have attracted negative attention for allowing brand-name pharma firms to pay generics companies to delay bringing lower-cost versions of brand-name drugs to market. However, PhRMA maintains that the settlements are "pro-consumer" and "often bring generics to market years before patent expiration."

"PhRMA continues to believe that legislation that would impose a blanket ban on certain types of patent settlements or otherwise prevent them could decrease the value of patents and reduce incentives for future innovation of new medicines," the trade group said in a statement.

"The courts and enforcement agencies like the Federal Trade Commission (FTC) are in the best position to review these settlements on a case-by-case basis to ensure that they are not harmful to competition," PhRMA stressed.

"By imposing a general ban or imposing harsh disincentives, pending legislation would effectively remove the decision-making process from this appropriate venue."

The pending bill is intended to address supplemental appropriations for the wars in Iraq and Afghanistan. However, such bills frequently end up with other provisions attached to them.

29th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....